-
Product Insights
Acral Lentiginous Melanoma - Drugs In Development, 2024
Empower your strategies with our Acral Lentiginous Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Acral lentiginous melanoma (ALM), also sometimes referred to as, simply, acral melanoma, is melanoma occurring on the hands and feet (palms, soles, fingers, toes, and nail units). This is is a subtype of cutaneous malignant melanoma. The condition can develop in normal-appearing skin or within an existing mole. It is comprised of malignant melanocytes, which can become invasive with time. The...
-
Sector Analysis
Melanoma - Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Melanoma–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional melanoma therapies was $5.5 billion in 2021. The growing aging population, leading to an increased diagnosed incidence of melanoma across age groups will drive market growth during the forecast period. Melanoma–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More About the Melanoma–Cell and Gene Therapies 15-Market Forecast Download a Free Report Sample The...
-
Sector Analysis
Melanoma – Global Drug Forecast and Market Analysis to 2029
Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body. Although melanoma has high survivability, it remains a significant health risk around the world. Where possible, melanoma is treated with surgery, with stage III patients likely to receive adjuvant therapy with either PD-1 inhibitors; BMS’ Opdivo or Merck & Co’s Keytruda or, if BRAF V600-positive, Novartis’ BRAF/MEK inhibitor combination Tafinlar + Mekinist. Metastatic...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.